neuroClues Raises €10 Million Series A to Revolutionize Early Diagnosis of Neurological Disorders

In a groundbreaking move for the MedTech industry, neuroClues—a French-Belgian startup—has successfully raised €10 million in a Series A funding round. With the backing of Teampact Ventures, White Fund, and the European Innovation Council (EIC) Fund, the company has now secured a total of €25 million in capital. This new infusion of funds marks a significant milestone for neuroClues as it aims to transform the early diagnosis of neurological disorders with its innovative technology.

Pioneering Early Diagnosis in Neurology

Founded in 2020 by Antoine Pouppez, Pierre Daye, and Pierre Pouget, neuroClues is on a mission to empower clinicians with advanced tools for detecting neurological disorders long before symptoms become visible. The startup has developed a compact, non-invasive medical device that leverages eye movement analysis to provide objective biomarkers for neurological conditions. This technology, already CE-marked as Class IIa, promises to revolutionize how clinicians approach diagnosis and monitoring in their practice.

The company highlights a growing need for such innovations, as neurodegenerative diseases increasingly affect one in three individuals. Alarmingly, conditions like Parkinson’s disease are expected to double in prevalence by 2040, with many patients suffering irreversible damage before accurate diagnosis. neuroClues addresses this urgent need with its state-of-the-art device that offers critical insights within minutes, directly during patient consultations.

Expanding the Frontiers of Neurological Analysis

The new funding will accelerate neuroClues' commercial expansion across Europe, where it has already deployed over 30 devices in various medical institutions. The technology is gaining traction in university hospitals, private neurology practices, and research centers across France, Belgium, Italy, Germany, Switzerland, the Netherlands, and the UK.

neuroClues’ platform is designed to replace traditional, subjective methods like the “follow my finger” test with quantified data, offering clinicians a more reliable means of identifying early signs of disorders such as Parkinson’s, Alzheimer’s, and concussion-related impairments. As the device is used more widely, it gathers valuable data that enhances its ability to differentiate between specific conditions, making it an indispensable tool in modern neurology.

Strategic Growth and Investment Opportunities

The company’s growth is further supported by its involvement in prestigious clinical cohorts, such as those at the Paris Brain Institute, and its selection for a mega-cohort study involving 25,000 participants. These initiatives will help develop the first large-scale normative database of oculomotor biomarkers, setting a new standard in the field.

neuroClues is also broadening its commercial reach under the leadership of newly appointed Chief Commercial Officer Bart Stulens, a former VP at Medtronic. The startup is actively recruiting in France and exploring distributor agreements across the EMEA region. In a move to democratize investment opportunities, neuroClues has opened a limited tranche of €1.5 million on LITA, allowing individual investors to join under the same terms as institutional backers.

Why This Matters

For startups, founders, and investors, neuroClues exemplifies the potential of innovative MedTech solutions to address significant healthcare challenges. Its success underscores the importance of integrating technology with medical practice to improve patient outcomes. The company’s strategic partnerships, robust funding, and expanding market presence make it a compelling case study in how disruptive technologies can scale and impact global health.

Conclusion

neuroClues is poised to become a pivotal player in the MedTech landscape, with its innovative approach to diagnosing neurological disorders early. By combining cutting-edge technology with strategic growth initiatives, the startup is setting a new benchmark in neurological diagnostics. As it continues to expand, neuroClues offers a glimpse into the future of healthcare—where early intervention and precise diagnosis are within reach.

Source: /